



**MULTNOMAH COUNTY
AGENDA PLACEMENT REQUEST
NOTICE OF INTENT**

(Revised: 9/23/13)

APPROVED: MULTNOMAH COUNTY
BOARD OF COMMISSIONERS
AGENDA # e.4 DATE 12/4/14
MARINA BAKER, ASST BOARD CLERK

Board Clerk Use Only

Meeting Date: 12/04/2014
Agenda Item #: C.4
Est. Start Time: 9:30 A.M.
Date Submitted: 11/19/14

Agenda Title: NOTICE OF INTENT to submit an application to Boehringer Ingelheim for up to \$15,000.

Note: This APR is for NOI's only. APRs are available for other types of submittals. Title should not be more than 2 lines but be sufficient to describe the action requested.

Requested Meeting Date: December 4, 2014 **Time Needed:** Consent Item
Department: Health **Division:** Nursing Practice
Contact(s): Sarah Rawson, Mary Anna Gordon, and Alison Frye
503.988.8732
971.266.7156
503.988.8687 **Ext.** _____ **I/O Address:** 160/8; 160/8;160/9
Presenter Name(s) & Title(s): N/A – Consent Item

General Information

1. What action are you requesting from the Board?

Authorization for the Director of the Health Department to submit an application to Boehringer Ingelheim Pharmaceuticals, Inc. for up to \$15,000 to pilot training using clinical simulation.

2. Please provide sufficient background information for the Board and the public to understand this issue. Please note which Program Offer this action affects and how it impacts the results.

Boehringer Ingelheim Pharmaceuticals, Inc. provides Medical Education Grant support for specific independent educational activities for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health. An independent educational program may be at the national, regional or local level and may include, but is not limited to, live and interactive didactic presentations (e.g., symposia at major educational meetings, grand rounds, regional workshops), web-based programs, print and electronic monographs and other innovative educational formats.

MCHD proposes the development and implementation of a diabetes-focused training for nurses and support staff using simulation methodology. Simulation is used to imitate clinical scenarios that force participants to develop and enhance skills in assessment, critical thinking, problem solving and analysis. As we move to Alternative Payment Models, where providers are paid a per-member/per month sum to care for patients, it is critical that nurses, medical assistants, and other professionals are well trained in the most current approaches and therapeutic modalities to provide the best, most cost effective care that leads to the best health outcomes. This training is especially important in the area of diabetes, as the percentage of diabetic patients who have their diabetes under control is a performance measure for MCHD Community Health Centers, and diabetes has been named a training priority for MCHD's healthcare workforce. Diabetes is also one of the 11 therapeutic subject areas for which Boehringer Ingelheim is interested in providing funding. Simulation training is the perfect medium for these training needs since it provides an opportunity to practice skills, such as patient education, that cannot be honed in classroom or didactic approaches to learning.

3. Explain the fiscal impact (current year and ongoing).

This grant would provide the Health Department with up to \$15,000 over approximately a one year period to pilot the training.

4. Explain any legal and/or policy issues involved.

None

5. Explain any citizen and/or other government participation that has or will take place.

None.

Grant Application/Notice of Intent

If the request is a Grant Application or Notice of Intent, please answer all of the following in detail:

• **Who is the granting agency?**

The granting agency is Boehringer Ingelheim Pharmaceuticals, Inc.

• **Specify grant (matching, reporting and other) requirements and goals.**

No matching is required. The goal is to support innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes. An end of cycle report is required after completion of education activities.

• **Explain grant funding detail – is this a one-time only or long term commitment?**

One time only.

• **What are the estimated filing timelines?**

There is no deadline for the application. Submission will likely occur the week of December 8, after approval from the board.

• **If a grant, what period does the grant cover?**

We expect to pilot 2 trainings between March 1, 2015 and February 28, 2016.

• **When the grant expires, what are funding plans?**

The training curriculum and simulation lab will be developed by the end of the funding period, so no further funding will be required.

- **Is 100% of the central and departmental indirect recovered? If not, please explain why.**

Indirect costs are not allowable under this funding opportunity.

Required Signatures

**Elected Official
or Department/
Agency Director:**

Wendy Lear on behalf of Joanne Fuller/s/ **Date:** 11/18/2014

Budget Analyst:

Wendy Lin-Kelly /s/ **Date:** 11/19/2014

Note: Please submit electronically. We are no longer using actual signatures. Insert names of your approvers followed by /s/. Please insert date approved